Advertisement

Supportive Care in Cancer

, Volume 24, Issue 4, pp 1571–1581 | Cite as

Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study

  • Susana Pereira
  • Filipa Fontes
  • Teresa Sonin
  • Teresa Dias
  • Maria Fragoso
  • José M. Castro-Lopes
  • Nuno LunetEmail author
Original Article

Abstract

Purpose

The purposes of this study were to estimate the incidence of chemotherapy-induced peripheral neuropathy (CIPN) and to identify its main determinants and impact in patient-reported outcomes.

Methods

We performed a prospective cohort study including 296 patients with incident breast cancer submitted to chemotherapy, followed for 1 year. Patients with incident CIPN were reevaluated 6 months after this diagnosis. Relative risks (RR) with 95 % confidence intervals (95 % CI) were computed to quantify the relation between different clinical characteristics and the occurrence of CIPN, using Poisson regression. The variation of patient-reported outcomes between baseline and 1-year follow-up assessments was compared between patients with and without CIPN.

Results

The cumulative incidence of CIPN in the first year after diagnosis was 28.7 % (95 % CI 23.8–34.1), and more than 80 % of the patients were still symptomatic after 6 months. Among the latter, there was a significant decrease in the median total neuropathy score, clinical version (7 versus 4) between the two periods. In multivariable analysis, the risk of CIPN was higher for treatment with docetaxel (cumulative doses ≤300 mg/m2, RR = 6.96, 95 % CI 2.53–19.10; >300 mg/m2, RR = 13.32; 95 % CI 4.11–43.14). Alcohol consumption and diabetes were not significantly associated with CIPN. There were no significant differences in the variation of patient-reported outcomes between the baseline and 1-year follow-up evaluations.

Conclusions

CIPN was frequent in this contemporary cohort of early-stage breast cancer patients and was strongly associated with docetaxel-based regimens. Symptoms persisted for at least 6 months in most patients, but severity was low and CIPN had no impact on patient-reported outcomes.

Keywords

Breast neoplasm Peripheral nerve injuries Quality of life 

Notes

Funding

The work of FF was supported by the “Fundação para a Ciência e a Tecnologia” (grant number SFRH/BD/92630/2013), and data management activities were supported by the Chair on Pain Medicine of the Faculty of Medicine, University of Porto and by the Grünenthal Foundation—Portugal.

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer. [http://globocan.iarc.fr/] (Accessed on 1 January 2015)
  2. 2.
    De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R (2014) Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE—5-a population-based study. Lancet Oncol 15(1):23–34CrossRefPubMedGoogle Scholar
  3. 3.
    Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, Altekruse S, et al. (2013) SEER Cancer Statistics Review, 1975–2011, National Cancer Institute. Bethesda, MD: SEER. Available from: [http://seer.cancer.gov/csr/1975_2011/] (Accessed on 1 November 2014)
  4. 4.
    Miltenburg NC, Boogerd W (2014) Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev 40(7):872–882CrossRefPubMedGoogle Scholar
  5. 5.
    Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew KD (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125(3):767–774CrossRefPubMedGoogle Scholar
  6. 6.
    Eckhoff L, Knoop A, Jensen M, Ewertz M (2015) Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer 51(3):292–300CrossRefPubMedGoogle Scholar
  7. 7.
    Jaggi AS, Singh N (2012) Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 291(1–3):1–9CrossRefPubMedGoogle Scholar
  8. 8.
    Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC (2008) Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15(29):3081–3094CrossRefPubMedGoogle Scholar
  9. 9.
    Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13(1):27–46CrossRefPubMedGoogle Scholar
  10. 10.
    Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470CrossRefPubMedGoogle Scholar
  11. 11.
    Ewertz M, Qvortrup C, Eckhoff L (2015) Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol 54(5):587–591CrossRefPubMedGoogle Scholar
  12. 12.
    Kudlowitz D, Muggia F (2014) Clinical features of taxane neuropathy. Anti-Cancer Drugs 25(5):495–501CrossRefPubMedGoogle Scholar
  13. 13.
    Rivera E, Cianfrocca M (2015) Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol 75(4):659–670PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    De Iuliis F, Taglieri L, Salerno G, Lanza R, Scarpa S (2015) Taxane induced neuropathy in patients affected by breast cancer: literature review. Crit Rev Oncol HematolGoogle Scholar
  15. 15.
    Vincenzi B, Frezza AM, Schiavon G, Spoto C, Silvestris N, Addeo R, Catalano V, Graziano F, Santini D, Tonini G (2013) Identification of clinical predictive factors of Oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer 21(5):1313–1319CrossRefPubMedGoogle Scholar
  16. 16.
    Ramanathan RK, Rothenberg ML, de Gramont A, Tournigand C, Goldberg RM, Gupta S, Andre T (2010) Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies. Ann Oncol 21(4):754–758CrossRefPubMedGoogle Scholar
  17. 17.
    de la Morena BP, Conesa MA, Gonzalez-Billalabeitia E, Urrego E, Garcia-Garre E, Garcia-Martinez E, Poves MZ, Vicente V, de la Pena FA (2015) Delayed recovery and increased severity of paclitaxel-induced peripheral neuropathy in patients with diabetes. J Natl Compr Cancer Netw 13(4):417–423Google Scholar
  18. 18.
    Uwah AN, Ackler J, Leighton JC Jr, Pomerantz S, Tester W (2012) The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Clin Colorectal Cancer 11(4):275–279CrossRefPubMedGoogle Scholar
  19. 19.
    Pereira S, Fontes F, Sonin T, Dias T, Fragoso M, Castro-Lopes J, Lunet N (2014) Neurological complications of breast cancer: study protocol of a prospective cohort study. BMJ Open 4(10), e006301PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Freitas S, Simoes MR, Alves L, Santana I (2011) Montreal cognitive assessment (MoCA): normative study for the Portuguese population. J Clin Exp Neuropsychol 33(9):989–996CrossRefPubMedGoogle Scholar
  21. 21.
    Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRefPubMedGoogle Scholar
  22. 22.
    Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 28(2):193–213CrossRefPubMedGoogle Scholar
  23. 23.
    Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370CrossRefPubMedGoogle Scholar
  24. 24.
    CTCAE (2010) Cancer Therapy Evaluation Program, Common terminology criteria for adverse events, version 4.0. DCTD, NCI, NIH, DHHS, [http://ctep.cancer.gov/] (Accessed on 1 January 2012).
  25. 25.
    Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T (1999) Total neuropathy score: validation and reliability study. Neurology 53(8):1660–1664CrossRefPubMedGoogle Scholar
  26. 26.
    Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J (2008) Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 70(18):1630–1635CrossRefPubMedGoogle Scholar
  27. 27.
    Griffith KA, Merkies IS, Hill EE, Cornblath DR (2010) Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst 15(4):314–325CrossRefPubMedGoogle Scholar
  28. 28.
    Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24(10):1633–1642CrossRefPubMedGoogle Scholar
  29. 29.
    Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC (1993) Neurotoxicity of taxol. J Natl Cancer Inst Monogr 15:107–115PubMedGoogle Scholar
  30. 30.
    Eckhoff L, Knoop AS, Jensen MB, Ejlertsen B, Ewertz M (2013) Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat 142(1):109–118CrossRefPubMedGoogle Scholar
  31. 31.
    Eckhoff L, Nielsen M, Moeller S, Knoop A (2011) TAXTOX—a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. Acta Oncol 50(7):1075–1082CrossRefPubMedGoogle Scholar
  32. 32.
    Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249(1):9–17CrossRefPubMedGoogle Scholar
  33. 33.
    Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L (2014) Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer 22(8):2261–2269CrossRefPubMedGoogle Scholar
  34. 34.
    Pace A, Nistico C, Cuppone F, Bria E, Galie E, Graziano G, Natoli G, Sperduti I, Jandolo B, Calabretta F, Tomao S, Terzoli E (2007) Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue? Clin Breast Cancer 7(7):550–554CrossRefPubMedGoogle Scholar
  35. 35.
    Argyriou AA, Polychronopoulos P, Koutras A, Iconomou G, Gourzis P, Assimakopoulos K, Kalofonos HP, Chroni E (2006) Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer 14(3):223–229CrossRefPubMedGoogle Scholar
  36. 36.
    Freilich RJ, Balmaceda C, Seidman AD, Rubin M, DeAngelis LM (1996) Motor neuropathy due to docetaxel and paclitaxel. Neurology 47(1):115–118CrossRefPubMedGoogle Scholar
  37. 37.
    Griffith KA, Dorsey SG, Renn CL, Zhu S, Johantgen ME, Cornblath DR, Argyriou AA, Cavaletti G, Merkies IS, Alberti P, Postma TJ, Rossi E, Frigeni B, Bruna J, Velasco R, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey DJ, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG (2014) Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study. J Peripher Nerv Syst 19(2):127–135PubMedCentralCrossRefPubMedGoogle Scholar
  38. 38.
    de Carvalho BM, Kosturakis AK, Eng C, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Wang XS, Cleeland CS, Dougherty PM (2014) A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy. Cancer Res 74(21):5955–5962CrossRefGoogle Scholar
  39. 39.
    Boyette-Davis JA, Eng C, Wang XS, Cleeland CS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Zhang H, Dougherty PM (2012) Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy. Clin Cancer Res 18(11):3180–3187PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Vichaya EG, Wang XS, Boyette-Davis JA, Mendoza TR, He Z, Thomas SK, Shah N, Williams LA, Cleeland CS, Dougherty PM (2013) Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy. Cancer Chemother Pharmacol 71(6):1531–1540PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Kosturakis AK, He Z, Li Y, Boyette-Davis JA, Shah N, Thomas SK, Zhang H, Vichaya EG, Wang XS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Cleeland CS, Dougherty PM (2014) Subclinical peripheral neuropathy in patients with multiple myeloma before chemotherapy is correlated with decreased fingertip innervation density. J Clin Oncol 32(28):3156–3162PubMedCentralCrossRefPubMedGoogle Scholar
  42. 42.
    Osmani K, Vignes S, Aissi M, Wade F, Milani P, Levy BI, Kubis N (2012) Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation. J Neurol 259(9):1936–1943CrossRefPubMedGoogle Scholar
  43. 43.
    Davis ID, Kiers L, MacGregor L, Quinn M, Arezzo J, Green M, Rosenthal M, Chia M, Michael M, Bartley P, Harrison L, Daly M (2005) A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 11(5):1890–1898CrossRefPubMedGoogle Scholar
  44. 44.
    Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, Watanaboonyakhet P, Weiss M, Adams PT, Dockter TJ, Loprinzi CL (2014) North Central Cancer Treatment Group/Alliance trial N08CA—the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120(12):1890–1897PubMedCentralCrossRefPubMedGoogle Scholar
  45. 45.
    Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS (2013) Randomized double-blind placebo-controlled trial of acetyl-l-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 31(20):2627–2633PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Susana Pereira
    • 1
    • 2
  • Filipa Fontes
    • 2
    • 3
  • Teresa Sonin
    • 1
  • Teresa Dias
    • 1
  • Maria Fragoso
    • 1
  • José M. Castro-Lopes
    • 4
    • 5
  • Nuno Lunet
    • 2
    • 3
    Email author
  1. 1.Portuguese Institute of Oncology of PortoPortoPortugal
  2. 2.EPIUnit—Institute of Public Health, University of Porto (ISPUP)PortoPortugal
  3. 3.Department of Clinical Epidemiology, Predictive Medicine and Public Health, Faculty of MedicineUniversity of PortoPortoPortugal
  4. 4.Department of Experimental Biology, Faculty of MedicineUniversity of PortoPortoPortugal
  5. 5.Institute for Molecular and Cell Biology (IBMC)University of PortoPortoPortugal

Personalised recommendations